Skip to content

Microencapsulated Fish Oil or Conjugated Linoleic Acid in Metabolic Syndrome

Hypocaloric Diet With or Without Microencapsulated Fish Oil or Conjugated Linoleic Acid on Oxidative Stress and Cardiovascular Risk Factors in Women With Metabolic Syndrome Genotyped for Polymorphisms in the Genes PPAR Gamma 2 (Pro12Ala) and Adiponectin (G276T)

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02183922
Enrollment
37
Registered
2014-07-08
Start date
2008-05-31
Completion date
2011-01-31
Last updated
2014-07-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anthropometric Measure, Blood Pressure, Insulin Resistance, Lipid Profile, Oxidative Stress

Brief summary

Our aim was to assess the effects of a hypocaloric diet, including diet fruit jelly with microencapsulated fish oil or conjugated linoleic acid or placebo, on anthropometry, body composition, insulin resistance and lipid profile in women with metabolic syndrome and genotype Pro12Pro in the PPAR gamma 2 gene.

Interventions

DIETARY_SUPPLEMENTmicroencapsulated conjugated linoleic acid

The microencapsulated conjugated linoleic acid received light fruit jam with microencapsulated conjugated linoleic acid (3 g/day) during 12 weeks.

DIETARY_SUPPLEMENTmicroencapsulated fish oil

The microencapsulated fish oil group received light fruit jam with microencapsulated fish oil (3 g/day) during 12 weeks.

DIETARY_SUPPLEMENTlight fruit jam

The placebo group received light fruit jam (15 g/day) during 12 weeks.

Sponsors

Rio de Janeiro State Research Supporting Foundation (FAPERJ)
CollaboratorOTHER_GOV
Universidade Federal do Rio de Janeiro
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
FACTORIAL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
FEMALE
Age
30 Years to 45 Years
Healthy volunteers
Yes

Inclusion criteria

* adults women (30-45 years old); * diagnosis of metabolic syndrome, as defined by the International Diabetes Federation; * Pro12Pro genotype in gene PPARγ2.

Exclusion criteria

Participants were excluded if they: * Were allergic to strawberries or fish * Were pregnant or lactating * Took fatty acid supplements * Had undergone bariatric surgery or were being treated nutritionally or pharmacologically for reducing BM, or had taken anti-obesity drugs during the previous three months

Design outcomes

Primary

MeasureTime frameDescription
Oxidative stress biomarkerChange from baseline at 12 weeksPlasma malondialdehyde levels

Secondary

MeasureTime frameDescription
Insulin resistanceChange from baseline at 12 weeksHomeostatic Model Assessment-Insulin Resistance index, adiponectin, glucose and insulin levels
Lipid profileChange from baseline at 12 weeksTotal cholesterol, LDL-cholesterol, VLDL-cholesterol, HDL-cholesterol and triglycerides serum levels and EPA, DHA and total conjugated linoleic acid plasma levels
Anthropometric measuresChange from baseline at 12 weeksBody weight, body mass index and waist circumference
Body composition measuresChange from baseline at 12 weeksFat-free mass and fat mass
Blood pressureChange from baseline at 12 weeksSystolic blood pressure and diastolic blood pressure

Countries

Brazil

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026